DaVita Announces Chief Operating Officer Transition

* Reuters is not responsible for the content in this press release.

Thu Oct 23, 2008 6:00am EDT

EL SEGUNDO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- DaVita Inc.
(NYSE: DVA), today announced that Joe Mello will retire as the company's Chief
Operating Officer on December 31, 2008.  Dennis L. Kogod has been promoted to
Chief Operating Officer effective January 1, 2009.  Dennis currently serves as
DaVita's President -- West, a role he has occupied since October 2005.
    (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)
Joe Mello, who served as Chief Operating Officer since June 2000, will
continue with the company on a full-time basis through May 2009 and on a
part-time basis thereafter.
    Dennis joined DaVita in 2005, following DaVita's acquisition of Gambro
Healthcare, Inc.  From January 2004 until joining DaVita, Mr. Kogod served as
Gambro's president and chief operating officer-west.
Kent Thiry, Chief Executive Officer of DaVita, commented:  "This planned
succession is yet another in the long list of wonderful contributions Joe
Mello has made to the DaVita community.  Our immense gratitude for Joe's
historical contributions is matched by our confident anticipation of the
future contributions Dennis will make.  When we acquired Gambro a few years
ago we added many new assets to our enterprise -- the leadership of Dennis was
among the most valuable.  In addition, both Dennis and I are thrilled that we
will still benefit from Joe's experience in select areas going forward."
    DaVita Inc. is a leading provider of kidney care in the United States,
providing dialysis services and education for patients with chronic kidney
failure and end stage renal disease. DaVita manages over 1,300 outpatient
facilities and acute units in over 700 hospitals located in 43 states and the
District of Columbia, serving more than 107,000 patients.
SOURCE  DaVita Inc.

LeAnne Zumwalt of DaVita Inc., +1-650-696-8910
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.